Bioscan Research has raised $1 million in its seed funding round. Unicorn India Ventures led this round. The strategic investment is crucial for the innovation-driven medtech company as it attempts to grow its specialized non-invasive diagnostic solutions. Bioscan Research can enhance its positioning, research and development capabilities, and commercialization process in the domestic and foreign healthcare markets.

Primary objective and core innovation

This investment round is designed to fill an urgent void in emergency medical treatment and early diagnosis of disease. Bioscan Research specializes in innovative, low-cost, non-invasive diagnostic solutions aimed at fast clinical diagnosis. 

The liquid capital will help the company implement a transparent expansion plan. It is moving its proprietary technologies into general geographic areas and working to define or adjust clinical and commercial structures essential for widespread deployment.

Bioscan Research has set out a clear plan for using the $1 million raised in this seed round. The capital will be deployed strategically to scale up market expansion, acquire further regulatory licenses in target zones, conduct continuous product upgradations, and invest in ongoing new IP research and development. 

The fundraising follows strong commercial results and rapid market adoption in the previous year. Over the past 12 months, based on ongoing product improvements and increased clinical acceptance, the revenue and adoption for Bioscan Research is projected to have grown 5x. The impressive traction is driven by the need of healthcare providers for objective, pre-symptomatic diagnostic solutions that are easily deployable in emergency units and trauma wards.

Building off this momentum in operation, Bioscan Research has developed ambitious growth targets for its next operational stage. The startup aims for a growth of 3x in the next year. In terms of commercial distribution, the enterprise is expected to increase its network coverage in different parts of India and actively identify potential avenues for market entry across countries. 

Their record in commercialization in national markets combined with strategic venture investment gives them a solid foundation for this global scaling stage. Currently, only 50% to 90% of patients who sustain a mild traumatic brain injury are identified because traditional diagnostic workflows are insufficient. Bioscan Research co-founder Anupam Lavania and co-founder Shilpa Malik emphasized the transformative potential of their optical sensing technology. 

This seed funding will directly help the company overcome structural limitations of traditional diagnostic equipment, the co-founders said. Bioscan Research plans to deliver a non-invasive, hands-free solution to empower patients and deliver timely healthcare services, whether in urban centres with major hospitals or rural areas lacking adequate resources, all over India and in international markets.

Market performance and founders perspectives

The fundraising comes on the back of strong commercial performance and rapid market adoption over the past year. Bioscan Research recorded a 5x growth in revenue and product adoption over the last 12 months, driven by continuous product improvements and expanding clinical acceptance. This impressive traction reflects a growing demand among healthcare providers for objective, pre-symptomatic diagnostic tools that can be easily deployed in emergency units and trauma centers.

Building on this operational momentum, Bioscan Research has established aggressive growth targets for its next operational phase. The startup plans to achieve a 3x growth over the upcoming 12 months. To reach this benchmark, the enterprise is preparing to expand its commercial distribution network across various regions in India while actively pursuing international market entry. 

The combination of proven commercial performance in domestic markets and strategic capital backing provides a solid foundation for this global scaling phase. Between 50% and 90% of patients experiencing mild traumatic brain injuries currently go unidentified due to the limitations of conventional diagnostic workflows. By offering a portable, non-invasive alternative, Bioscan Research intends to ensure that patients receive timely care regardless of whether they are in major urban hospitals or underserved rural healthcare settings across India and international markets.

Conclusion

The $1 million seed round from Unicorn India Ventures is a testament to Bioscan Research’s innovative early-stage brain injury diagnostics solution. The startup’s proprietary CEREBO device combines mechanics with optics and electronics and machine learning to solve a long-standing challenge in global trauma care. With a clear path to 3x growth over the next 12 months and a proven 5x growth over the last 12 months, Bioscan Research is in a strong position to scale the business, secure key regulatory approvals, and bring much-needed diagnostic technology to healthcare providers around the world.